Table 3. Toxicities and feeding status according to SMM status.
| Without low SMM (n = 55) | Low SMM (n = 42) | P-value | |
|---|---|---|---|
| Mucositis* | 0.41 | ||
| I/II | 49 (89.1%) | 35 (83.3%) | |
| III/IV | 6 (10.9%) | 7 (16.7%) | |
| Dermatitis* | 0.98 | ||
| I/II | 51 (92.7%) | 39 (92.9%) | |
| III/IV | 4 (7.3%) | 3 (7.1%) | |
| Dysphagia* | 0.11 | ||
| I/II | 23 (41.8%) | 11 (26.2%) | |
| III/IV | 32 (58.2%) | 31 (73.8%) | |
| Dysphagia before treatment | 0.01 | ||
| I/II | 48 (87.3%) | 27 (64.3%) | |
| III/IV | 7 (12.7%) | 15 (35.7%) | |
| Weight loss during treatment | 0.40 | ||
| <10% | 45 (81.8%) | 37 (88.1%) | |
| > = 10% | 10 (18.2%) | 5 (11.9%) | |
| Feeding-tube prior treatment | 0.46 | ||
| No | 38(69.1%) | 26(61.9%) | |
| Yes | 17(30.9%) | 16(38.1%) |
SMM skeletal muscle mass; Significance p calculated by Pearson’s chi-squared test, Mucositis, Dermatitis, and Dysphagia grouped according to CTCAE v5.0 [22]
*highest CTCAE classification during treatment